Future Medical Promotion Organization

What Future Medical Promotion Organization does

Future Medical Promotion Organization (一般社団法人未来医療推進機構) is a Japanese general incorporated foundation established in November 2019 through a partnership between 21 private companies and Osaka Prefecture to drive the industrialization of future and regenerative medicine. It serves as the core operator of Nakanoshima Qross, a 57,075 sqm, 16-story medical complex in Osaka's Nakanoshima district that opened in June 2024 and is structured into three integrated facilities: the Future Medical R&D Center (creation), the Future Medical MED Center (medical practice), and the Nakanoshima International Forum (sharing). The organization functions as a quasi-public platform hub rather than a product company, curating an ecosystem of more than 80 tenants spanning startups (e.g., Qualips, Kyoto University iPS Cell Research Foundation/CiRA_F), large pharmaceutical and medical device enterprises (Astellas Pharma, Terumo, Nippon Life), and regulatory bodies (PMDA liaison office), and reports engagement with partners across more than 50 countries.

Its service portfolio combines physical infrastructure with programmatic offerings: facility rental and tenant services for R&D centers and offices; the NQ Portal one-stop service platform (NQ Concierge, NQ Selection, NQ Marutto Logi) for regenerative medicine supply chain; the advanced CDMO human resource training program (priced at ¥20,000–¥50,000 per course with tenant discounts); startup acceleration programs (NQ Deep Tech Studio, NQ Global Startup Gateway, NQ Health Accelerator, Bio-Catalyst AI Accelerator); the VMaCS cell stable supply value chain consortium with a pilot plant opened June 2026; and the Qrossover Lounge Yume co-creation space. Revenue is generated through facility rental/tenant services, training and education fees, and event/conference hosting, supplemented by government subsidies (MHLW drug discovery cluster program, Osaka Prefecture support) and membership contributions from founding companies.

The foundation has executed a dense run of international MoUs in 2026 — with Biocom (March), Boehringer Ingelheim Japan (February), Sumitomo Corporation (May), BioLabs (May), and MedTech Innovator APAC (July) — and a four-party Osaka Life Science Nexus partnership with Osaka Prefecture, Nippon Life, and CIC Japan (July 2026). It is governed by a board chaired by Yoshiki Sawa, who concurrently serves as Director-General of Osaka Keishatsu Hospital and a specially appointed professor at Osaka University.

Name

Future Medical Promotion Organization

Legal name

一般財団法人未来医療推進機構

Website

https://nakanoshima-qross.jp

Company type

Private

Founded year

2019

Operating status

Operating

Short description

Future Medical Promotion Organization is a Japanese non-profit foundation that operates Nakanoshima Qross, an Osaka-based ecosystem hub accelerating regenerative medicine industrialization for startups, researchers, pharma/medical device companies, and government partners.

Ownership category

akta.pro rank

Product category

Healthcare Innovation Hub / Regenerative Medicine Ecosystem Services

NAICS

Voluntary Health Organizations (813212)

SIC

Services-Health Services (8000)

akta.pro primary industry

Health Access & Social Care Innovations (Community Health, Telehealth for Underserved) (BPAGALAG)

akta.pro secondary industries

Global Supply Chain, Procurement & Market-Shaping Partnerships (Medicines/Diagnostics/Vaccines) (HLAJAOAK), Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI)

Keywords

• Regenerative medicine ecosystem
• Medical innovation hub
• CDMO training programs
• Startup incubation services
• Healthcare facility management

Headquarters

HQ city

Osaka

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Facility Rental and Tenant Services: Operating a medical complex with rental spaces for R&D centers, medical facilities, and office spaces for companies engaged in regenerative medicine and future healthcare development.
2. Training and Education Programs: CDMO human resource training programs with fees ranging from 20,000-50,000 yen per course for general participants and discounted rates for tenants.
3. Event and Conference Services: Hosting venues and events including conferences, seminars, and networking opportunities for the life sciences ecosystem.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Future Medical Promotion Organization operates Nakanoshima Qross, a 16-story medical complex in Osaka that houses the Future Medical R&D Center, Future Medical MED Center, and Nakanoshima International Forum. The foundation runs an integrated ecosystem that brings together medical institutions, pharmaceutical and medical device companies, startups, and support organizations to accelerate the industrialization of regenerative medicine and future healthcare, offering tenant facility services, CDMO training programs, startup acceleration, one-stop supply chain services, and international partnership facilitation.

Product overview

Nakanoshima Qrossは、未来医療推進機構が 운영하는再生医療・ライフサイエンス分野の国際的な産業化拠点です。3つの主要施設（未来医療R&Dセンター、未来医療MEDセンター、中之島国際フォーラム）で構成され、14の事業・サービス產品ポートフォリオを有しています。核となるのはNQポータル（NQコンシェルジュ、NQセレクション、NQまるっとロジ）と中之島クロス・ワンストップサービスを組み合わせた再生医療サプライチェーン支援基盤です。これに人才bao成（高度CDMO人材bao成プログラム、NQ Deep Tech Studio、COO人材bao成プログラム）、スタートアップ支援（NQ Global Startup Gateway、Bio-Catalyst AIアクセラレーター、ヘルスアクセラレーター）、細胞製造基盤（VMaCSパイロットインプラント）、国際連携（NQ Global Life Sciences Cluster）、交流・共創場（Qrossover Lounge 夢）を加え、未来医療の「創造」「実践」「共有」を循環させる有機的なエコシステムを提供しています。

Differentiator

Problem solved

Functional benefit

Brands

• NQコンシェルジュ: Provides various knowledge related to regenerative medicine and cell therapy to support regenerative medicine workers.
• NQセレクション
• NQまるっとロジ
• NQ Deep Tech Studio
• NQ Global Startup Gateway
• NQ Open Talk
• NQ Works Seminar
• NQ Health Accelerator Program
• NQ Global Life Sciences Cluster
• VMaCS (Value Chain for Stable Supply of Cells)
• 高度CDMO人材育成拠点
• Qross Talk
• Qrossover Lounge 夢
• NQ Science Bar
• NQ Health Accelerator Program (NQHA)

Products and services

• NQ Portal (One-Stop Service for Regenerative Medicine Supply Chain) Membership-based portal providing regenerative medicine information, content, and one-stop services spanning market exploration to commercialization. Composed of three integrated services: NQ Concierge, NQ Selection, and NQ Marutto Logi.
• Nakanoshima Qross Advanced CDMO Human Resource Training Program Systematic training program for Contract Development and Manufacturing Organization (CDMO) professionals in regenerative and cell medicine, adopted as part of the MHLW FY2024 supplementary budget Drug Discovery Cluster Campus project.
• Qrossover Lounge Yume (Co-Creation Space)

Quantifiable outcome

• Supported 22 startups in first year of drug discovery program with integrated assistance
• +1 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability11 records

Feature3 records

Partnerships

15 partnerships are on record, tiered core and minor.

• Osaka PrefecturecoreStrategic or Co-development Partner · 14 July 2026Core government partner supporting facility operations and various programs including NQ Deep Tech Studio, CDMO training, and international partnership initiatives.
• Nippon Life InsurancecoreStrategic or Co-development Partner · 3 July 2026Four-party partnership including Osaka Prefecture, Nippon Life, and CIC Japan to form a life sciences innovation ecosystem centered on Nakanoshima Qross, including the Osaka Life Science Nexus facility.
• CIC JapancoreStrategic or Co-development Partner · 3 July 2026Co-developer of Osaka Life Science Nexus, bringing global startup ecosystem expertise to the Nakanoshima Qross location.
• MedTech Innovator APACcoreStrategic or Co-development Partner · 2 July 2026Partnership with world-class MedTech accelerator to provide global market development support for Japanese startups through the NQ Deep Tech Studio program.
• BIPROGY CorporationminorStrategic or Co-development Partner · 28 May 2026Joint initiative to provide DotHealth body measurement service at Nakanoshima Qross, contributing to health monitoring and research data collection.
• West Japan Railway Company (JR West)minorStrategic or Co-development Partner · 28 May 2026Partnership in PHR Connect joint venture providing DotHealth measurement services at the facility.
• Hakuhodo Inc.minorStrategic or Co-development Partner · 28 May 2026Partnership in PHR Connect joint venture providing DotHealth measurement services at the facility.
• BioLabscoreStrategic or Co-development Partner · 18 May 2026MoU signed with BioLabs, a membership-based international network headquartered in Cambridge, Massachusetts, to strengthen international collaboration in the life sciences sector.
• Sumitomo CorporationcoreStrategic or Co-development Partner · 14 May 2026Collaboration MoU signed to strengthen the ecosystem and create new businesses in drug discovery, regenerative medicine, and advanced medical fields. Combines NQ's innovation infrastructure with Sumitomo's global network and business development capabilities.
• BiocomcoreStrategic or Co-development Partner · 30 March 2026Partnership with Biocom, California's largest and most influential life sciences organization, to strengthen international collaboration in the life sciences field. The MoU was signed on March 30, 2026.
• Boehringer Ingelheim JapancoreStrategic or Co-development Partner · 24 February 2026MoU signed for open innovation in drug discovery, aiming to accelerate social implementation of promising Japanese drug discovery seeds and strengthen international competitiveness of Japan's drug discovery ecosystem.
• Astellas Pharma Inc.coreStrategic or Co-development PartnerCo-organizer of Regenerative Medicine Symposium and ongoing collaboration in drug discovery cluster campus initiatives for regenerative medicine industrialization.
• Ceragef BioScience Inc.minorStrategic or Co-development PartnerJoint venture between Astellas Pharma and Yaskawa Electric developing digital innovation in cell medicine manufacturing, with facilities located within Nakanoshima Qross.
• PMDA (Pharmaceuticals and Medical Devices Agency)minorStrategic or Co-development PartnerTenant with liaison office in Future Medical R&D Center, providing regulatory guidance for pharmaceutical and medical device development.
• LINK-J (Life Science Innovation Network Japan)minorStrategic or Co-development PartnerTenant organization promoting life science innovation networking and collaboration within the ecosystem.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• MaRS Discovery District: MaRS is a Toronto-based urban innovation district that combines startup incubation, corporate partnerships, and ecosystem events in a single physical facility. Like Nakanoshima Qross, MaRS serves as a central hub connecting startups, enterprises, and government stakeholders in health/cleantech.
• Biocom: Biocom is California's largest life science industry association, providing advocacy, networking, and partnership services to life science companies — a partner of Future Medical Promotion Organization since March 2026. Biocom is a comparable industry-association/ecosystem-orchestrator model for life sciences.
• BioLabs: BioLabs is a membership-based international lab/coworking network for life sciences startups headquartered in Cambridge, MA; it signed an MoU with Future Medical Promotion Organization in May 2026. BioLabs is a direct peer in life-science-focused coworking and incubator services targeting early-stage biotech ventures.
• CIC (Cambridge Innovation Center): CIC operates shared innovation campuses with curated startup communities; its CIC Japan arm (a partner of Future Medical Promotion Organization) runs the Osaka Life Science Nexus co-located within Nakanoshima Qross. CIC is the most directly comparable company model — facility-based community/incubator with tenant services — though applied globally and to multiple verticals.
• JLABS (Johnson & Johnson Innovation): JLABS is a Johnson & Johnson-operated global life science incubator network offering lab space, programming, and corporate partnership access to early-stage biotech startups, with an APAC presence. It is a direct comparator in dedicated life-science startup incubation services.
• CIC Innovation Campus (Cambridge US): CIC's Cambridge campus is one of the largest startup coworking/incubator complexes in the US, offering shared facilities, programming, and corporate partnerships — directly comparable to Nakanoshima Qross's integrated facility model across R&D, practice, and event/exchange functions.
• LINK-J (Life Science Innovation Network Japan): LINK-J is a life science-focused community/networking organization operating in Tokyo's Nihonbashi district; it is also a tenant within Nakanoshima Qross. Both organizations perform overlapping ecosystem-orchestration, networking, and event functions for Japanese life science innovators.

Regional players

• Juno Bio (Singapore) / Biopolis Cluster: Biopolis is Singapore's purpose-built biomedical research and innovation hub operated by A*STAR; comparable in concept as a single-location life science R&D, incubation, and translational medicine hub, but serving APAC outside Japan.
• Foundation for Biomedical Research and Innovation (Kobe) / Kobe Biomedical Innovation Cluster: The Kobe Biomedical Innovation Cluster is a competing Japanese life science ecosystem initiative with similar translational research, company incubation, and ecosystem development goals. It is a regional competitor targeting similar Japanese regenerative medicine and biotech tenants.

Broad incumbents

• Alexandria Real Estate Equities: Alexandria is a large US REIT that develops and operates life science real estate clusters (Mission Bay, Cambridge, etc.) housing biotech tenants. It is comparable in operating model (purpose-built life science real estate with tenant ecosystem) but at much larger scale and as a for-profit public entity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/nq_miraikiko
• Instagraminstagram.com/nq_miraikiko

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Future Medical Promotion Organization